MVMahesha Vankalakunti

Mahesha Vankalakunti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahesha Vankalakunti has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Profile and Outcome of C3-Dominant Glomerulonephritis: Retrospective Study

    by Vishrut Khullar, Attur Ravindra Prabhu, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Indu Ramachandra Rao, Srinivas Vinayak Shenoy, Mohan V. Bhojaraja, Gaurvi Piplani, Mahesha Vankalakunti

    Background: Complement 3 (C3)-dominant glomerulonephritis (GN) are rare diseases resulting from alternative complement pathway dysregulation; they include C3 glomerulopathy (C3G), paraprotein-associated GN, and C3-dominant infection-related GN (IRGN). To our knowledge, long-term follow-up studies of clinical profile and outcomes of this rare disorder are sparse. We studied kidney histopathology baseline findings, outcomes, treatment, and its complications of C3-dominant GN in our setting. Objectives: We studied the clinical, pathological profiles, and outcomes of patients with C3-dominant GN. Methods: This study was a single centre, retrospective, case record based observational study at a tertiary care hospital in Southern India. Consecutive patients of C3-dominant GN on kidney biopsy from 2013 to 2023 were included. Demography, laboratory and histopathological data, treatment and outcomes were studied. Results: Of 2,175 kidney biopsies, 141 (6.48%) showed C3-dominant GN; 74 (52.5%) C3G, 67 (47.5%) IRGN. Median age was 43 years (IQR 29–59.5), males 90 (63.8%). Preceding skin/throat infections were seen in 32/141 (22.7%). At presentation, median serum creatinine was 1.7 mg/dL (IQR: 1.2–3.6), eGFR <60 mL/min/1.73 m2 in 91/141 (64.5%), 111/141 (78.7%) had low serum C3 levels. Nephrotic proteinuria was seen in 65/141 (46%), Crescents in 45 (31.9%). Remission was partial in 38/141 (27%), complete in 45/141 (31.9%) and 31/141 (22%) progressed to end-stage kidney disease (ESKD). On immunosuppression, commonest infection was pneumonia in 15/70 (21.4%) and 27/141 (19.1%) died at an average follow-up of 25.7 months. Diabetes mellitus, percentage sclerosis, and presence of crescents predicted development of CKD stage 5. Conclusion: Over 10 years, C3-dominant GN represented 6.48% of kidney biopsies. Nephrotic proteinuria and kidney failure are common at presentation with 58% achieving some remission, 22% going on to ESKD and mortality of 19%.


  • Open Access

    Role of C4d and CD68 in kidney biopsy as novel prognostic markers for IgA nephropathy; a single-center study from India

    by Pritam Khomane, Ashwin Somwarpet Prabhakar, Shankar Prasad Nagaraju, Indu Ramachandra Rao, Kiran Krishne Gowda, Mahesha Vankalakunti, Ravindra Prabhu Attur, Srinivas Vinayak Shenoy, Dharshan Rangaswamy, Mohan Varadanayakanahalli Bhojaraja, et al.

    Introduction: IgA nephropathy (IgAN) is a common primary glomerulonephritis worldwide. C4d and CD68 could be useful prognostic markers in this disease. Objectives: This study was conducted to assess the clinical and prognostic implications of C4d and CD68 staining in patients with IgAN. Materials and Methods: This is a retrospective single-center observational study. Baseline characteristics and laboratory details were recorded. Renal biopsy was reported according to the MEST-C classification along with further staining for C4d and CD68 by immunohistochemistry. Primary and secondary outcomes were progression to end-stage renal disease (ESRD) and all-cause mortality during follow-up, respectively. The effect of C4d and CD68 along with other risk factors on outcomes was studied. Results: Sixty patients with primary IgAN were analyzed with a median follow-up of 17 months. Forty were males, with a mean age of 39±16 years, and median estimated glomerular filtration rate (eGFR) of 36.5 mL/min/1.73 m2 with a median urine protein/creatinine ratio of 1.9 g/g, at the time of kidney biopsy. In our patients, macroscopic hematuria (n=2: 3.3%) was rare, while 15 (25%) of patients had nephrotic-range proteinuria. Most biopsies showed sclerosis 43 (71.7%) followed by interstitial fibrosis and tubular atrophy (IFTA) 32(53.3%). Meanwhile, crescents were seen in 20 (33.3%). About 39 (65%) of patients had glomerular C4d positivity and 10 (16.7%) had tubulointerstitial CD68 positivity while, none having glomerular CD68 positivity. Glomerular C4d and tubulointerstitial CD68 positivity had lower eGFR, higher proteinuria at presentation (P<0.05) and faster progression to ESRD (glomerular C4d-odds ratio [OR]: 5.7 [95% CI: 1.4-22.5]); tubulointerstitial CD68 OR: 5.4 [ 95% CI: 1.2-23.95]. Other risk factors predicting progression were eGFR at presentation (OR: 0.9 [95% CI: 0.89-0.99], presence of sclerosis OR: 6.5 [95% CI: 1.32-32.06] and IFTA OR: 21.4 [ 95% CI: 4.3-108]). Conclusion: In our study, IgAN patients presented in the later stages of chronic kidney disease, with the majority being diagnosed at stage 3 of this disease. Macroscopic hematuria was rare and nephrotic syndrome and crescents were common. Glomerular C4d and tubulointerstitial CD68 were associated with lower eGFR and more rapid progression.


  • Open Access

    C3 glomerulopathy in children: experience at a resource-limited center

    by Soumya Reddy, Abhishek Ghante, Mahesha Vankalakunti, Anil Vasudevan

    In children, C3 glomerulopathy (C3G) is a heterogeneous disease characterized by diverse clinicopathological profiles and kidney outcomes. However, diagnostic work-up in resource-limited settings is challenging because of the unavailability of complement assays and limited access to electron microscopy or genetic testing. This study aimed to describe the clinicopathological features and response to immunosuppression and evaluate renal outcomes among children with C3G in a resource-limited setting. This retrospective cohort study involved a review of the hospital records of 46 children (2013-2021) diagnosed with C3G on kidney biopsy. Their clinical, laboratory, treatment, and outcome details at onset and follow-up were noted. The mean (SD) age was 9 (4) years. The common presentation was acute nephritis (27 [58.6%]), while one in five (19.5%) presented with rapidly progressive glomerulonephritis. Focal-crescentic glomerulonephritis (14 [30.4%]) was the common histological pattern. Electron microscopy was performed in 22 (47.8%), of which 17 were C3 glomerulonephritis (C3GN) and four were dense deposit disease (DDD). None of the patients underwent complement assay or genetic testing. Almost two-thirds (63%) received empirical immunosuppressive therapy, most commonly steroids. Of the 31/46 who completed follow-up (median [IQR] duration, 11.5 [6-24] months), six (19.4%) demonstrated complete kidney recovery, while the other 25 (80.7%) had kidney sequelae; of them, five (16.1%) progressed to end-stage kidney disease and two (4.3%) died by the last follow-up. Pediatric C3G has a variable clinicopathological spectrum, while DDD is less common. Most patients present with glomerulonephritis and significant morbidities. The lack of genetic and C3Nephritic factor testing is a barrier to the comprehensive phenotyping and management of C3G in resource-limited settings.


  • Open Access

    Tenofovir induced acute kidney injury and its outcome; an Indian perspective

    by Sreedhara C. Gurusiddaiah, Bhushan C Shetty, Kishan Aralapuram, Shashank Shetty, Mythri Shankar, Mahesha Vankalakunti

    Introduction: Tenofovir remains the cornerstone drug in various antiretroviral regimens and is commonly associated with renal failure in susceptible individuals with a renal biopsy suggestive of proximal tubular injury. Objectives: To investigate clinical, histopathological and outcome findings in tenofovir-induced nephrotoxicity patients. Patients and Methods: Between August 1, 2014, and March 31, 2017, an observational study was conducted in a government-run tertiary care facility in South India. All patients receiving a regimen based on tenofovir disoproxil fumarate (TDF) and testing positive for human immunodeficiency virus (HIV) were included. A renal biopsy was performed when needed. Results: A total of 27 cases were identified, with a mean age of 45.03± 12.95 years, while 19 (70%) of them were men. Mean creatinine and mean proteinuria among the participants were 5.78 ±2.71 mg/dL and 1643.96 ±1056.44 mg/dL, respectively, at the time of the renal biopsy. Interval between TDF treatments to kidney biopsies ranged between 7 to 52 weeks with mean (±SD) of 30.8±22 weeks. Phosphaturia and glycosuria were found in 10 (37.03%) and 8 (29.5%) patients respectively, all of whom had normoglycemia. In contrast to the remaining 13 instances, which all had moderate to severe diffuse inflammation, 14 patients exhibited toxic proximal tubular damage along with mild and localized interstitial inflammation. Hemodialysis was required by 10 individuals. A total of 22 patients were monitored after TDF was stopped, while 17 (77.27%) of them had fully recovered renal function at the end of monitoring period. Conclusion: This study demonstrates that TDF nephrotoxicity is a reversible form of toxic acute tubular necrosis with concurrent interstitial inflammation that affects the proximal tubules. As a result, it is crucial to carefully monitor renal parameters in these patients.


  • Open Access

    C1q nephropathy in children with nephrotic syndrome: Treatment strategies and outcomes

    by Saumil Gaur, Reeba Patrick, Mahesha Vankalakunti, Kishore Phadke

    J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society


  • Open Access

    Dense deposit disease involving C3 and C4d Deposits

    by M Vankalakunti, R Augustine, R Jangamani, V Siddini, R Bonu, K Babu, Sh Ballal

    Dense deposit disease (DDD), earlier called Type II membranoproliferative glomerulonephritis is distinct disease having frequent relapses reaching end-stage kidney disease by 10-year in up to 50%–60% of cases and high recurrence rate in the allograft. The term DDD is derived from its distinctive ribbon-like osmiophilic deposits in the lamina densa of glomerular basement membrane by electron microscopy. Pathogenetically, alternate pathway dysfunction leads to this disease, which is diagnosed by ultrastructure. Herein, we describe our observation of C4d positivity in an adolescent boy with DDD.


  • Open Access

    Sunitinib induced nephrotic syndrome and thrombotic microangiopathy

    by M Vankalakunti, Pk Jha, V Siddini, R Bonu, Gk Prakash, K Babu, Hs Ballal

    Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction and nephrotic syndrome. However, simultaneous occurrence of nephrotic syndrome and renal dysfunction in a patient treated with sunitinib is rare. We report a case of metastatic RCC treated with sunitinib for 22 months who presented with nephrotic syndrome and renal dysfunction. Renal biopsy was diagnostic of thrombotic microangiopathy with diffuse effacement of podocytic foot process.